Effect of Hemodialysis on 7-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation

Buronova, N.; Kamishima, Kazuho; Yamaguchi, Junichi; Jujo, Kentaro; Watanabe, Erisa; Inagaki, Yoshiaki; Kishi, Shohei; Wada, Akira; Hatakeyama, S.; Watanabe, Masahiro; Nakao, Masashi; Okayama, Dai; Arashi, Hiroyuki; Yamada, Noriko; Takagi, Atsushi; Hagiwara, Nobuhisa

doi:10.1253/circj.cj-15-0113

Cited by 14 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dialysis is a wellknown predictor for MACE after coronary stenting. 2,8, 25 Although only 4.9% of the patients were on dialysis, dialysis was the strongest predictor for MACE in the present study ( Figure S1). Whereas clinically driven TLR rate was 2.5% at 1 year and 3.7% at 3 years in non-dialysis patients, it was 13.1% at 1 year and 18.4% at 3 years in dialysis patients.…”

Section: Predictors Of Macementioning

confidence: 59%

Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan

Aoki

Kozuma

Awata

et al. 2016

Circ J

Self Cite

View full text Add to dashboard Cite

906AOKI J et al. Circulation JournalOfficial Journal of the Japanese Circulation Society http://www. j-circ.or.jp EES), have not been fully evaluated in routine clinical practice in Japan. Therefore, we evaluated 3-year clinical outcomes after EES implantations in a real-world setting at 47 Japanese sites using the EES Japan PMS database. Methods Subjects and Follow-upCoCr-EES PMS Japan is a prospective multicenter registry enrolling 2,000 patients who received CoCr-EES. The study was designed to evaluate the safety and efficacy of the CoCr-EES in routine clinical practice shortly after the launch of ate stent thrombosis and late in-stent restenosis are the 2 major limitations of first-generation drug-eluting stents (DES). 1,2 Second-generation DES are associated with significantly lower in-stent restenosis rate and lower rate of late stent thrombosis as compared with first-generation DES. 3-6 Therefore, second-generation DES are used currently as the first-line coronary stents in routine clinical practice. Clinical outcomes of first-generation DES, such as sirolimusand paclitaxel-eluting stents, in earlier Japanese post-marketing surveillance studies (PMS) have been published previously, 7-9 but long-term clinical outcomes for second-generation DES, such as cobalt-chromium everolimus-eluting stents (CoCr-

show abstract

Section: Predictors Of Macementioning

confidence: 59%

Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan

Aoki

Kozuma

Awata

et al. 2016

Circ J

Self Cite

View full text Add to dashboard Cite

show abstract

“…In terms of HD patients undergoing percutaneous coronary intervention, several reports have already revealed that HD patients have a poorer prognosis than non-HD patients. 11,12 However, only a few studies to date have examined the clinical outcomes in HD patients with CLI who undergo EVT, and compared the prognosis as well as its predictors between HD and non-HD patients. 13,14 In addition, causes of death in HD patients after EVT for CLI are not clarified in detail, although cardiovascular death is believed to be the leading cause.…”

mentioning

confidence: 99%

Clinical outcome and its predictors in hemodialysis patients with critical limb ischemia undergoing endovascular therapy

Kataoka

Yamaguchi

Nakao

et al. 2017

J Interven Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reasons for this are considered to be multifactorial. First, dialysis patients tend to have more advanced comorbidities including hypertension, diabetes mellitus, peripheral artery disease, and heart failure than nondialysis patients . These underlying diseases, especially heart failure in this study, may be associated with in‐hospital adverse outcomes in dialysis patients undergoing PCI.…”

Section: Discussionmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

“…Previous studies have reported that dialysis patients have an increased risk of adverse outcomes during and after PCI compared with nondialysis patients . However, details on the characteristics and outcomes after PCI in dialysis patients remain unclear because the sample size of this group of patients is limited . Although some previous studies have assessed clinical outcomes after PCI in dialysis patients with acute coronary syndrome (ACS), few have specifically examined this matter in patients with stable CAD .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An overview of percutaneous coronary intervention in dialysis patients: Insights from a Japanese nationwide registry

Numasawa

Inohara

Ishii

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives This study sought to provide an overview of percutaneous coronary intervention (PCI) in dialysis patients from a Japanese nationwide registry. Background Little is known about dialysis patients undergoing PCI because few are enrolled in clinical trials. Methods We analyzed 624,900 PCI cases including 41,384 dialysis patients (6.6%) from 1,017 Japanese hospitals between 2014 and 2016. We investigated differences in characteristics and in‐hospital outcomes between dialysis and nondialysis patients, and assessed factors associated with an increased risk of adverse outcomes. Results Dialysis patients had more comorbidities than nondialysis patients and higher rates of complications including in‐hospital mortality (3.3% vs. 1.5%, respectively, in the acute coronary syndrome [ACS] cohort, 0.2% vs. 0.1% in the non‐ACS cohort) and bleeding complications requiring blood transfusion (1.1% vs. 0.4% in ACS, 0.5% vs. 0.2% in non‐ACS). Dialysis was significantly associated with an increased risk of in‐hospital mortality (odds ratio [OR]: 1.42, 95% confidence interval [CI]: 1.24–1.62 in ACS, OR: 2.25, 95% CI: 1.66–3.05 in non‐ACS) and bleeding (OR: 1.60, 95% CI: 1.30–1.96 in ACS, OR: 1.55, 95% CI: 1.27–1.88 in non‐ACS). For dialysis patients, age, acute heart failure, and cardiogenic shock were associated with an increased risk of in‐hospital mortality in the ACS cohort, whereas age, female gender, and history of heart failure were associated with higher in‐hospital mortality in the non‐ACS cohort. Conclusions PCI was widely performed for dialysis patients with either ACS or non‐ACS in Japan. Dialysis patients had a greater risk of adverse outcomes than nondialysis patients after PCI.

show abstract

Effect of Hemodialysis on 7-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation

Cited by 14 publications

References 37 publications

Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan

Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan

Clinical outcome and its predictors in hemodialysis patients with critical limb ischemia undergoing endovascular therapy

An overview of percutaneous coronary intervention in dialysis patients: Insights from a Japanese nationwide registry

Contact Info

Product

Resources

About